keyword
MENU ▼
Read by QxMD icon Read
search

golimumab

keyword
https://www.readbyqxmd.com/read/28217835/symmetrical-drug-related-intertriginous-and-flexural-exanthema-sdrife-induced-by-golimumab
#1
Shiang-Yu Yang, Cheng-Che Lan, Stephen Chu-Sung Hu
No abstract text is available yet for this article.
February 20, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28216195/golimumab-in-real-life-settings-2-years-drug-survival-and-predictors-of-clinical-outcomes-in-rheumatoid-arthritis-spondyloarthritis-and-psoriatic-arthritis
#2
Florenzo Iannone, Leonardo Santo, Maria Grazia Anelli, Romano Bucci, Angelo Semeraro, Laura Quarta, Francesca D'Onofrio, Antonio Marsico, Giorgio Carlino, Oriana Casilli, Fabio Cacciapaglia, Carmelo Zuccaro, Paola Chiara Falappone, Francesco Paolo Cantatore, Maurizio Muratore, Giovanni Lapadula
OBJECTIVES: To assess the drug survival of golimumab, and predictors thereof, in patients affected with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) in a prospective observational cohort. METHODS: This is a non-interventional, longitudinal study on RA, SpA, and PsA patients starting treatment with golimumab. Endpoints were the 2 years persistence rate of golimumab and predictors of therapy discontinuation. Drug retention was analyzed using Kaplan-Meier and Cox models...
January 18, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28213565/anti-tnf-induced-remission-in-very-early-peripheral-spondyloarthritis-the-crespa-study
#3
Philippe Carron, Gaëlle Varkas, Heleen Cypers, Liesbet Van Praet, Dirk Elewaut, Filip Van den Bosch
OBJECTIVE: To evaluate the efficacy and safety of golimumab to induce clinical remission in patients with very early, active peripheral spondyloarthritis (pSpA). METHODS: Clinical REmission in peripheral SPondyloArthritis is a monocentric study of golimumab treatment in patients with pSpA. All patients fulfilled the Assessment of SpondyloArthritis international Society classification criteria for pSpA, with a symptom duration ≤12 weeks. Patients were randomised 2:1 to receive golimumab 50 mg every 4 weeks or matching placebo for 24 weeks...
February 17, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28205212/sarcoidosis-extent-relates-to-molecular-variability
#4
Calixte S Monast, Katherine Li, Marc A Judson, Robert P Baughman, Eric Wadman, Rosemary Watt, Philip E Silkoff, Elliot S Barnathan, Carrie Brodmerkel
The molecular basis of sarcoidosis phenotype heterogeneity and its relationship to effective treatment of sarcoidosis have not been elucidated. Peripheral samples from sarcoidosis subjects who participated in a phase 2 study of golimumab (anti-TNFα) and ustekinumab (anti-IL12p40) were used to measure the whole blood transcriptome and levels of serum proteins. Differential gene and protein expression analyses were used to explore the molecular differences between sarcoidosis phenotypes as defined by extent of organ involvement...
February 16, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28175091/p407-prospective-evaluation-of-clinical-efficacy-and-safety-of-golimumab-in-biologic-experienced-and-na%C3%A3-ve-patients-with-moderate-to-severe-ulcerative-colitis-experience-from-a-tertiary-referral-centre
#5
B Orlandini, G Dragoni, S Bagnoli, S Deiana, G Macrì, F Rogai
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175026/p226-comparison-of-four-different-immunoassays-for-measuring-golimumab-and-anti-golimumab-antibody-concentration-in-patients-with-ulcerative-colitis
#6
S Paul, G Duru, A De Vries, J C Marini, D Aoucheta, F Cornillie, S Nancey, I Detrez, A-E Berger, A Gils, X Roblin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172973/p621-efficacy-and-safety-of-golimumab-in-ulcerative-colitis-preliminary-data-from-a-multicenter-italian-study
#7
F Bossa, M R Valvano, G Costantino, E Vinci, A Rispo, M Mendolaro, M Patturelli, E Shaini, S Mazzuoli, C RIcciardelli, A Tursi, A Lauria, P Paese, A Azzarone, L Sebkova, G Pranzo, W Fries, F Castiglione, M Cappello, A Privitera, B Principi, A Andriulli
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172970/p446-characterization-of-ulcerative-colitis-patients-in-the-golimumab-pursuit-maintenance-study-post-hoc-analyses-of-patients-who-maintained-and-did-not-maintain-clinical-response-through-week-54
#8
W J Sandborn, P Rutgeerts, H Zhang, O J Adedokun, S Xu, R Shraim, C Marano
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172740/p686-application-of-dried-blood-spots-for-pharmacokinetic-profiling-of-golimumab-treated-patients-with-ulcerative-colitis
#9
I Detrez, V Ballet, G Van Assche, S Vermeire, M Ferrante, A Gils
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172612/p615-the-unfinished-symphony-golimumab-is-efficient-in-patients-with-refractory-crohn-s-disease
#10
T Greener, G Greenberg, H Steinhart, M Silverberg
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172577/p358-efficacy-of-golimumab-for-the-treatment-of-ulcerative-colitis-patients-in-clinical-practice-a%C3%A2-retrospective-cohort-study
#11
G Dufour, R Altwegg, J-C Valats, M Bismuth, N Funakoshi, F Gonzalez, L Caillo, P Pouderoux, P Blanc, G Pineton de Chambrun
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172482/p403-golimumab-therapy-for-ulcerative-colitis-an%C3%A2-irish-multicentre-experience
#12
J O'Connell, C Rowan, G Chan, G Harkin, V Parihar, J Layden, S Patchett, R Stack, P MacMathuna, A O'Toole, B Ryan, F MacCarthy, S McKiernan, G Doherty, L Eagan, D Kevans
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28158970/tumor-necrosis-factor-alpha-inhibitors-have-no-effect-on-a-human-t-lymphotropic-virus-type-i-htlv-i-infected-cell-line-from-patients-with-htlv-i-associated-myelopathy
#13
Shoichi Fukui, Hideki Nakamura, Yoshiko Takahashi, Naoki Iwamoto, Hiroo Hasegawa, Katsunori Yanagihara, Tatsufumi Nakamura, Akihiko Okayama, Atsushi Kawakami
BACKGROUND: While tumor necrosis factor alpha (TNF-α) inhibitors (TNFi) and other biologics are very effective against autoimmune diseases, they can also cause infectious diseases. Therefore, it is important to clarify whether the TNFi sometimes used to treat patients with rheumatoid arthritis (RA) complicated with human T-lymphotropic virus type-I (HTLV-I) infection have the unintended side effect of promoting HTLV-I proliferation. METHODS: We used the HTLV-I-infected cell line HCT-5, derived from spinal fluid cells of a patient with HTLV-I associated myelopathy, to evaluate the production of cytokines and chemokines, TNF-α receptor (TNFR), the expression of HTLV-I associated genes, the HTLV-I proviral load (PVL), the expression of HTLV-I structural protein, and apoptosis...
February 3, 2017: BMC Immunology
https://www.readbyqxmd.com/read/28138220/erratum-golimumab-in-radiographic-and-nonradiographic-axial-spondyloarthritis-a-review-of-clinical-trials-corrigendum
#14
(no author information available yet)
[This corrects the article on p. 2087 in vol. 10.].
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28124979/molecular-basis-for-the-neutralization-of-tumor-necrosis-factor-%C3%AE-by-certolizumab-pegol-in-the-treatment-of-inflammatory-autoimmune-diseases
#15
Jee Un Lee, Woori Shin, Ji Young Son, Ki-Young Yoo, Yong-Seok Heo
Monoclonal antibodies against TNFα, including infliximab, adalimumab, golimumab, and certolizumab pegol, are widely used for the treatment of the inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Recently, the crystal structures of TNFα, in complex with the Fab fragments of infliximab and adalimumab, have revealed the molecular mechanisms of these antibody drugs. Here, we report the crystal structure of TNFα in complex with the Fab fragment of certolizumab pegol to clarify the precise antigen-antibody interactions and the structural basis for the neutralization of TNFα by this therapeutic antibody...
January 23, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28121204/efficacy-of-golimumab-for-preventing-large-joint-destruction-in-patients-with-rheumatoid-arthritis-as-determined-by-the-arashi-score
#16
Katsuaki Kanbe, Koei Oh, Junji Chiba, Yasuo Inoue, Masashi Taguchi, Akiko Yabuki
OBJECTIVES: To investigate the inhibitory effect of golimumab on large joint destruction in patients with rheumatoid arthritis. METHODS: We recruited 45 patients with rheumatoid arthritis and evaluated the radiographic severity of large joint destruction using the ARASHI (assessment of rheumatoid arthritis by scoring of large joint destruction and healing in radiographic imaging) score. We evaluated 450 large joints including the elbow, shoulder, hip, knee and ankle at baseline and 52 weeks after treatment with golimumab...
January 25, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28120279/update-on-the-use-of-biologic-therapy-in-ulcerative-colitis
#17
REVIEW
Aakash Aggarwal, Timothy Sabol, Haleh Vaziri
Ulcerative colitis (UC) is a major form of inflammatory bowel disease and is characterized by chronic inflammation of the colon and rectum and by alternating periods of flares and remissions. Symptoms may include rectal bleeding, abdominal pain, and diarrhea. The pathogenesis of UC is complex and involves a combination of immune dysregulation, genetics, environmental factors, and microbiota. The goal of medical treatment is to induce and maintain remission. Traditionally, the treatment options for UC included 5-aminosalicylates, corticosteroids, and immunomodulators...
January 24, 2017: Current Treatment Options in Gastroenterology
https://www.readbyqxmd.com/read/28103433/baseline-extent-of-damage-predicts-spinal-radiographic-progression-in-korean-patients-with-ankylosing-spondylitis-treated-with-golimumab
#18
Jeong Seok Lee, Yeong Wook Song, Tae Hwan Kim, Won Tae Jung, Seung Geun Lee, Sung Hwan Park, Gwan Gyu Song, Dae Young Yu, Stephen Xu, Eun Young Lee
Background/Aims: For patients with ankylosing spondylitis (AS), golimumab has consistent efficacy in controlling disease activity over 5 years but its benefit in preventing radiographic progression was less clear at 4 years. To predict radiographic progression, we analyzed the baseline characteristics of AS patients in a Korean population. Methods: Sixty-eight Korean patients with AS participated in the phase 3, multicenter, randomized, placebo-controlled, double-blind trial (GO-RAISE) which has previously been described...
January 20, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28094756/treatment-modifying-factors-of-biologics-for-psoriatic-arthritis-a-systematic-review-and-bayesian-meta-regression
#19
REVIEW
Eric Druyts, Jacqueline B Palmer, Chakrapani Balijepalli, Keith Chan, Mir Sohail Fazeli, Vivian Herrera, Jeroen P Jansen, Jay J H Park, Steve Kanters, Andreas Reimold
OBJECTIVES: The aim of this study was to explore factors that modify treatment effects of non-conventional biologics versus placebo in patients with psoriatic arthritis. METHODS: A systematic literature review and meta-regression was conducted. The biologics included etanercept, infliximab, adalimumab, golimumab, certolizumab, ustekinumab, tocilizumab, anakinra, abatacept, rituximab, and secukinumab. Outcomes included American College of Rheumatology (ACR) 20 and 50, Psoriasis Area Severity Index (PASI) 75, and 36-Item Short Form Health Survey (SF-36) Physical and Mental Component Summaries (PCS and MCS)...
January 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28078646/mucosal-healing-in-ulcerative-colitis-a-comprehensive-review
#20
REVIEW
Pedro Boal Carvalho, José Cotter
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by periods of remission and periods of relapse. Patients often present with symptoms such as rectal bleeding, diarrhea and weight loss, and may require hospitalization and even colectomy. Long-term complications of UC include decreased quality of life and productivity and an increased risk of colorectal cancer. Mucosal healing (MH) has gained progressive importance in the management of UC patients. In this article, we review the endoscopic findings that define both mucosal injury and MH, and the strengths and limitations of the scoring systems currently available in clinical practice...
January 11, 2017: Drugs
keyword
keyword
19896
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"